Webdisclosure.com

Search

ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23

Directive transparence : information réglementée

26/05/2023 08:15

Edison Investment Research Limited
OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23

26-May-2023 / 07:15 GMT/BST
The issuer is solely responsible for the content of this announcement.


 

London, UK, 26 May 2023

 

OSE Immunotherapeutics (OSE): Re-initiation – Milestones anticipated throughout FY23

OSE Immunotherapeutics has announced its FY22 results, providing financial and operational updates as the company continues to advance its key clinical assets. A confirmatory and potentially pivotal Phase III study is planned for Tedopi, OSE’s lead cancer vaccine candidate, which we expect to be initiated by end-FY23/early-FY24, and this would mark a significant clinical milestone, in our view. Additional upcoming catalysts for investor attention include readouts in Q423 for OSE-127, being investigated in a Phase II study in ulcerative colitis. OSE-127 had previously been subject to a two-step licensing option granted to Servier. However, following negative readouts from a Phase II Servier-sponsored trial in primary Sjögren’s syndrome, OSE and Servier have mutually decided to terminate the option license agreement. We value OSE at €280.8m or €15.2 per share, with Tedopi as the primary contributor to this valuation, for which we expect commercialisation in 2028.

 

We value OSE at €280.8m or €15.2 per share. Tedopi is the primary contributor to our valuation. We assume a licensing deal for Tedopi in 2027, worth up to €650m based on precedent deals for cancer vaccine technologies, and anticipate the commercialisation of this asset in 2028.


Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn        www.linkedin.com/company/edison-group-/

Twitter           www.twitter.com/Edison_Inv_Res

YouTube       www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1642113  26-May-2023 

fncls.ssp?fn=show_t_gif&application_id=1642113&application_name=news&site_id=symex